- Home
- J&J Innovative Medicine
J&J Innovative Medicine
What you need to know about Johnson & Johnson’s 2025 second-quarter earnings
Here’s an infographic breakdown of the company’s second-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.
What is wAIHA?
Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and a potential targeted treatment developed by Johnson & Johnson that’s currently in clinical trials.
What are clinical trials?
Behind every innovative medicine, treatment and therapy is a clinical trial. To help you understand them better, here’s a closer look at how they work.
Johnson & Johnson named to Fortune’s 2025 America’s Most Innovative Companies list
The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.
What is metastatic cancer?
The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.
Johnson & Johnson named a 2025 Fortune World’s Most Admired Company
A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.